Quantitative modeling of SARS-CoV-2 replication reveals phase-specific bottlenecks and antiviral targets

Viruses are not alive in the way we understand life; they are simple packages of genetic instructions that must hijack a living cell to reproduce. Once a virus like SARS-CoV-2 enters a human cell, it takes over the cell's machinery to build copies of itself. This process involves a complex, timed sequence of events: the virus first makes copies of its genetic code, then uses those copies to build the proteins needed to construct new virus particles, and finally assembles and releases those new particles to infect other cells. While scientists have long known that this sequence happens, the exact speed of each step and which specific parts of the process are most critical to the virus's success have remained difficult to pin down. Understanding these precise mechanics is essential because if we know exactly how the virus builds itself, we can identify the most effective points to interrupt the process with medicines.

In a new study, researchers set out to map this invisible factory floor with unprecedented precision. They focused on human lung cells, the primary target of the virus, and tracked the infection over the first 24 hours. Instead of just observing the final outcome, the team measured the amount of viral genetic material, the levels of viral proteins, and the number of infectious virus particles produced at many different moments during that day. They combined these high-resolution measurements with a computer model designed to simulate the biological rules of the virus. This model acted as a mathematical description of the virus's life cycle, allowing the scientists to calculate the speed of every step, from the creation of genetic copies to the release of new viruses, filling in gaps that are nearly impossible to measure directly in a lab.

The results provided a clear, quantitative picture of how the virus operates. The model showed that the virus's ability to replicate depends heavily on two specific bottlenecks: the speed at which it copies its genetic material and the efficiency with which it matures the proteins needed to build new virus particles. These two steps were identified as the dominant factors determining how quickly the infection spreads within a cell. To test if their model was truly accurate, the researchers challenged it with real-world data from experiments where the virus was treated with three different drugs: remdesivir, nirmatrelvir, and montelukast. The model successfully predicted how the virus would respond to each drug on its own and even correctly forecasted how the drugs would interact when used together.

Perhaps most significantly, the study helped settle a specific debate regarding how one of these drugs works. There had been uncertainty about whether montelukast, a medication originally developed for asthma, targeted a specific viral protein known as NSP1 or another protein called NSP5. By comparing different versions of their model against the experimental data, the researchers found strong evidence that montelukast targets NSP5, not NSP1. This distinction is important because it clarifies the drug's mechanism of action. The study does not claim to have solved the problem of treating the virus, but it has established a reliable framework. By turning the complex, hidden processes of viral replication into a predictable system, this work offers a new way to evaluate how well potential treatments might work before they are even tested in patients.